Does OLAPARIB Cause Tumour marker increased? 171 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 171 reports of Tumour marker increased have been filed in association with OLAPARIB (Lynparza). This represents 0.9% of all adverse event reports for OLAPARIB.
171
Reports of Tumour marker increased with OLAPARIB
0.9%
of all OLAPARIB reports
9
Deaths
11
Hospitalizations
How Dangerous Is Tumour marker increased From OLAPARIB?
Of the 171 reports, 9 (5.3%) resulted in death, 11 (6.4%) required hospitalization, and 1 (0.6%) were considered life-threatening.
Is Tumour marker increased Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for OLAPARIB. However, 171 reports have been filed with the FAERS database.
What Other Side Effects Does OLAPARIB Cause?
Death (4,378)
Malignant neoplasm progression (1,862)
Nausea (1,582)
Anaemia (1,455)
Fatigue (1,437)
Off label use (777)
Vomiting (642)
Drug ineffective (563)
Diarrhoea (514)
Asthenia (491)
What Other Drugs Cause Tumour marker increased?
PALBOCICLIB (817)
FULVESTRANT (408)
NIRAPARIB (356)
LETROZOLE (343)
RIBOCICLIB (317)
RUCAPARIB CAMSYLATE (257)
CAPECITABINE (228)
EVEROLIMUS (228)
ELACESTRANT (222)
ANASTROZOLE (142)
Which OLAPARIB Alternatives Have Lower Tumour marker increased Risk?
OLAPARIB vs OLARATUMAB
OLAPARIB vs OLECLUMAB
OLAPARIB vs OLIVE OIL\SOYBEAN OIL
OLAPARIB vs OLMESARTAN
OLAPARIB vs OLMESARTAN MEDOXOMIL